DUSA Pharmaceuticals, Inc. (Nsdaq: DUSA) s reporting preliminary results of a Phase 2 clinical trial investigating the use of the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE